Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes

Abstract

Malcolm Irani,1 Christopher Fan,1 Kerri Glassner,1– 3 Bincy P Abraham1– 3 1Houston Methodist Gastroenterology Associates, Houston Methodist Hospital, Houston, TX, USA; 2Weill Cornell Medical College, New York, NY, USA; 3Houston Methodist Academic Institute, Houston, TX, USACorrespondence: Bincy P Abraham, Houston Methodist Gastroenterology Associates, 6550 Fannin St, Suite 1201, Houston, TX, 77030, USA, Tel [phone], Email [email protected]: This review addresses appropriate patient selection for upadacitinib, a Janus kinase inhibitor approved by the FDA and EMA for treatment of moderately to severely active ulcerative colitis (UC). Janus kinase molecules can contribute to the inflammatory pathway, so inhibiting certain of them may prove efficacious in treating UC and may reduce safety concerns. Upadacitinib is the newest Janus kinase inhibitor to be approved for UC, so it is timely and relevant to review patient selection and when to consider this medication. We will discuss efficacy and safety data from the pivotal clinical trials on upadacitinib. These data can be shared with patients and can inform the use of these agents in clinical practice.Keywords: upadacitinib, ulcerative colitis, small molecule

Keywords

• upadacitinib
• ulcerative colitis
• small molecule